MSD

MSD Pharmaceuticals Private Limited is an affiliate of Merck & Co. Inc., USA. (also known as Merck Sharp & Dohme or MSD in many parts of the world), a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck Sharp & Dohme currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. With global headquarters in New Jersey, USA, Merck & Co. Inc. 2007 sales stood at US $24.2 billion with 59,800 employees and product sales spanning 140 countries worldwide. The Merck Manufacturing Division employs more than 12, 000 people at locations in 25 countries. UNPARALLELED SCIENTIFIC EXCELLENCE Merck & Co. Inc., USA success has always been based on innovation and scientific research. A commitment to excellence in research is at the heart of its philosophy and strategy. Since the founding of its research laboratories over 70 years ago, Merck & Co. Inc. has developed more than 100 new medicines and vaccines. The Merck Research Laboratories employs approximately 9,500 people at sites in the United States, Canada, Europe and Asia. In 2007 Merck & Co. Inc. invested US $4.9 billion in R&D. Currently Merck's priority areas of focus in therapeutic research include Alzheimer's disease, atherosclerosis, cardiovascular disease, diabetes, novel vaccines obesity, oncology, pain, and sleep disorders. These therapeutic areas were carefully chosen based on a set of criteria including unmet medical needs, scientific opportunity and commercial opportunity. Within these therapeutic areas, Merck & Co. Inc. has committed resources to achieve research breadth and depth and to develop best-in-class targeted and differentiated products that are valued highly by patients, payers and physicians. KEY GLOBAL PRODUCT PORTFOLIO Merck & Co. Inc. has one of the strongest pipelines of products globally. Some of the representative products are:

COZAAR / HYZAAR -medicines in the cardiovascular area GARDASIL medicine in the vaccine area JANUVIA medicine in the metabolics area SINGULAIR medicine in the respiratory area

VYTORIN and ZETIA medicines in the cardiovascular area through the MSD/Schering-Plough joint venture CARING FOR THE SOCIETY WE SERVE Merck & Co. Inc. embraces a commitment to its stakeholders, employees, neighbors, and others in the global communities where it lives and works. Its commitment is demonstrated by its work in more than 140 countries worldwide, through its philanthropic initiatives and ethical business practices. For over 100 years MSD has produced The Merck Manual, one of many initiatives to in form health related decision making that also include the Merck Institute of Aging & Health and the Merck Vaccine Network. Merck & Co. Inc. build high environmental and safety standards into all of their processes and activities and promote continuous improvement. COMMITTED TO INDIA FOR THE LONG TERM MSD was incorporated in India on 3rd December 2004. Since then the company has moved quickly in laying the foundation for a successful business in India. A business that is differentiated by its focus on putting patients first and launching innovative products those are relevant to India. MSD currently operates within three therapeutic areas, namely critical care, metabolic and vaccines. The company initiatives and new drugs address unmet medical needs for India. In addition to setting up a sales and marketing structure to market its best in class products in India, MSD is also coordinating research projects with clinical investigators in India's leading hospitals and universities. As a testimonial to MSD's scientific excellence the Indian Council of Medical Research (ICMR) has signed the first public private partnership with MSD. MSD currently employs more than 600 Indian professionals and has aggressive plans for growth. Become one of the top 5 pharmaceutical companies by 2015 by providing superior products to patients, compelling value to partners and becoming an employer of choice. The mission of Merck & Co. Inc. is to provide the society with superior products and services by developing innovations and solutions that improve the quality of

life and satisfy customer needs, and to provide employees with meaningful work and advancement opportunities, and investors with a superior rate of return. OUR VALUES:

Our business is preserving and improving human life. All of our actions must be measured by our success in achieving this goal. We value, above all, our ability to serve everyone who can benefit from the appropriate use of our products and services, thereby providing lasting consumer satisfaction. We are committed to the highest standards of ethics and integrity. We are responsible to our customers, to our employees and their families, to the environments we inhabit, and to the societies we serve worldwide. In discharging our responsibilities, we do not take professional or ethical shortcuts. Our interactions with all segments of society must reflect the high standards we profess. We are dedicated to the highest level of scientific excellence and commit our research to improving human and animal health and the quality of life. We strive to identify the most critical needs of consumers and customers, and we devote our resources to meeting those needs. We expect profits, but only from work that satisfies customer needs and benefits humanity. Our ability to meet our responsibilities depends on maintaining a financial position that invites investment in leading-edge research and that makes possible effective delivery of research results. We recognize that the ability to excel -- to most competitively meet societys and customers' needs -- depends on the integrity, knowledge, imagination, skill, diversity and teamwork of our employees, and we value these qualities most highly. To this end, we strive to create an environment of mutual respect, encouragement and teamwork -- an environment that rewards commitment and performance and is responsive to the needs of our employees and their families.

Management The core management team of MSD India consists of experts and achievers who are reputed for their professional acumen and respected for their ability to develop and cultivate the genius within their team, via an innovative ambience and challenging work.

Mr. K.G. Ananthakrishnan Chief Operating Officer Mr. K. G. Ananthakrishnan has been appointed as the COO, MSD India in November 2009 post Merck & Co, the parent company acquired Schering Plough. He has also served on the senior management team of Pfizer India and was a member of the Board of Directors of Capsugel Healthcare Ltd., a Pfizer affiliated company. Prior to Pfizer, Ananthakrishnan served in various senior positions with the former Pharmacia Corporation and Novartis. He has been actively involved in industry related matters and is a member of the Executive Committee & Chairman of the Technical Committee of Organisation of Pharmaceutical Producers of India [OPPI] Mr. Ananthakrishnan has a Masters degree in Marketing Management from Jamnalal Bajaj Institute of Management Studies, Mumbai.

Mr. Swadesh Behera, Director - Human Resources Mr. Swadesh Behera joined MSD in November 2007 as Director-HR. A senior Human Resources Professional with diverse sectoral experience in MNCs & Indian Organizations covering Pharmaceuticals, FMCG and Manufacturing, Swadesh has extensive change management experience include setting up of green field operations, building capabilities and talent acquisition during high growth phases of business, implementing appropriate HR interventions, Employee Transition

Management during business closures etc. In his current role as Director - HR he is responsible for the entire HR function of MSD India. Mr. Behera holds a Post Graduate degree in Personnel Management and Industrial Relations from Tata Institute of Social Sciences along with a PG in Sociology from Hyderabad Central University.

Ms. Annapurna Das, Associate Director Business Development and New Product Planning Ms. Annapurna Das joined Fulford in January 2007 as Associate Director Strategy & Business Development. She has an enriching experience of 12 years in leadership roles for all strategic planning and organization building within the sales & marketing as well as business development functions of various healthcare companies. Ms. Das is an MBA from Madurai Kamaraj University and holds a B.Tech. degree from BIT, Sindri.

Mr. A. S. Krishna, Director External Affairs Mr. A.S. Krishna joined MSD in November 2007 as Director External Affairs. Prior to MSD, he has worked with leading pharmaceutical companies like Pfizer and Johnson & Johnson as Director Public Affairs/Government Affairs. Having ample experience in maintaining amicable relationships with organizations and allies, his role at MSD includes managing the external environment, helping shape the public policies, managing subsidiary communication and running the CSR programme for the subsidiary. Mr. Krishna has an enriching experience of 18 years with the Tata Group of Companies and holds a Masters in Science.

Mr. Rajesh Marwaha Director - Finance Mr. Rajesh Marwaha joined MSD as the Finance Director in February 2008. He has spent six years in Dubai and two years in France as Regional Controller. At MSD

Mr. Marwaha supervises Accounting, Legal, Administration, Information Technology departments. With his abundant experience of 20 years of working with varied sectors like audit, FMCG and home appliances industry, he has helped streamline the organizations financial activities. Mr. Marwaha is a qualified Chartered Accountant from the CA Institute of India and a commerce graduate.

Mr. Sanjiv Navangul, Director - Chronic Care, Specialty Care, Disease Management Mr. Sanjiv Navangul joined MSD in 2007 as Director - Sales and Marketing. He is credited with having augmented sales of various healthcare companies and is a strategic marketer who has been lauded for his ethical and professional brand building approach. Mr. Navangul has a comprehensive experience of 20 years across India, Europe and South East Asia and is currently responsible for the planning of sales and marketing strategies for the Chronic Care Specialty and Disease Management portfolio of the company. Mr. Navangul is an MBA from the University of Pune and holds a Bachelors degree in Pharmacy from M.S University, Baroda.

Mr. Suresh Pattathil, Director - Primary Care and Institutional Sales Mr. Suresh Pattathil joined Fulford in October 2006 as Vice President Marketing & Sales Primary Care. He has earlier worked with Pharmacia Upjohn & Pfizer India and brings with him a 19 year long illustrious career in strategic roles for sales, marketing and L&D functions. His business insights, innovation and competitive edge have contributed towards the all around development of the organization. Mr. Pathathil is an MBA from Bangalore University and holds a Bachelors degree in Science from Bangalore University.

Mr. N. Ratnaji Rao, Associate Director Strategy & PRO

Mr. N. Ratnaji Rao joined MSD in January 2008 as Head Strategic Initiatives. Prior to joining MSD he has worked as a management consultant with KPMG and as a sales manager with IBM. Mr. Rao is an MBA from IIM Calcutta and holds a BE degree in electronics from Mumbai University.

Dr. Swashraya Shah, Medical Director, MSD India Dr. Swashraya Shah joined MSD in October 2007 as Medical Director. He has an enriching experience of 10 years as a Medical Director in leading pharmaceutical companies. Responsible for supervising the research and medical affairs team, Dr. Shah has also worked as a lecturer in prestigious colleges. Dr. Shah is an MD in Pharmacology and MBBS in medicine and surgery from Grant Medical College & JJ Group of Hospitals. At MSD, partnerships are not short term alliances to fill the pipeline, but we offer long term commitments to upgrade our access to the world of scientific innovations that exist outside our laboratories. Since its inception, MSD has maintained close and trustworthy relationships with leading companies. Our partnerships are our collaborative efforts to accomplish the aim of developing innovative and first in class products that transform basic medical practices, restore health and save lives. Partnerships at MSD have always been mutually beneficial as we recognize the value that strong and cooperative partnerships bring to the fields of medicine and research. Our valued partnerships includeRESEARCH & DEVELOPMENT: Advinus Therapeutics to develop drug candidates in metabolic diseases. Nicholas Piramal to research and develop new drugs for selected targets as provided by MSD. Orchid Pharma to identify and develop novel anti-bacterial and anti-fungal drug candidates. Ranbaxy to develop anti-bacterial and anti-fungal drug candidates.

PUBLIC PRIVATE PARTNERSHIP INDIAN COUNCIL OF MEDICAL RESEARCH MSD and Indian Council of Medical Research (ICMR), an autonomous body under the Ministry of Health & Family Welfare (MOHFW) entered into a collaboration on December 20, 2005 to study Merck & Co. Inc. investigational cervical cancer vaccine, GARDASIL (Quadrivalent Human Papillomavirus types 6, 11, 16, 18, recombinant vaccine) in the Indian population. Our public private partnership with ICMR spans a range of activities, starting with the design of a study to assess the use of GARDASIL in the Indian population. In addition to assistance with the study design, Merck & Co. Inc. will supply GARDASIL for use in the study. Upon completion of the study, the two partners aim to work together to assess the role of HPV Vaccine on the population of India and identify ways of providing access to HPV Vaccine, thus not just bringing the best of India to Merck & Co. Inc. but also bringing the best of Merck & Co. Inc. to India. OPPI Marketing Excellence Award 2007 for CANCIDAS Instituted by the Organization of Pharmaceutical Producers India (OPPI), the award seeks to recognize the work done by pharmaceutical companies in the field of marketing. MSD has won this prestigious award for adhering to the highest standards in the brand building exercise for the leading anti-fungal drug CANCIDAS. It won this award in the keenly contested field of new entrants. The much coveted award stands testimony to our professional, reputed and ethical marketing approach. Merck in News September 8, 2008 New survey helps identify strategies to address diabetes care and the global economic and social impact of type 2 diabetes Read more > December 20, 2005

MSD and Indian Council of Medical Research (ICMR), an autonomous body under the Ministry of Health & Family Welfare (MOHFW) announced a collaboration to study Mercks investigational cervical cancer vaccine, GARDASIL (Quadrivalent Human Papillomavirus types 6, 11, 16, 18, recombinant vaccine) in the Indian population.

Our passion is improving health. That is what keeps us at the forefront of scientific discovery and development. Behind each of our medicines and vaccines is a team of researchers who are leaders in their fields. People whose unwavering enthusiasm for finding new ways to prevent and treat disease is matched only by their unrelenting commitment to scientific excellence and patient safety. We are entering an exciting period with a strong product pipeline that targets a broad range of diseases. And we're looking ahead to the next generation of healthcare by using new techniques and technologies. Therapeutic Areas We focus our research on several key therapeutic areas, including:

Cardiovascular Diabetes and Obesity Bone, Respiratory, Immunology, and Dermatology Infectious Disease Oncology Neurosciences and Ophthalmology Women's Health and Endocrine

In the Pipeline From preclinical development to Phase III clinical trials, our passion for advancing health through science is evident in the breadth and depth of our pipeline. Critical Care Dedicated to putting patients first, Merck & Co. Inc. has developed over 100 pioneering medicines and vaccines since the founding of its research laboratories 70 years ago. Developing, discovering and bringing breakthrough medicines to find treatments for some of the most vexing medical problems in our times forms the core philosophy of MSD. MSD has been relentlessly working to transform cutting edge sciences into innovative medicines and groundbreaking medical solutions in order to aid clinicians caring for critically ill patients, thereby helping in reducing mortality in ICU. Our innovations in critical care available in India are INVANZ CANCIDAS ZIENAM

Metabolics
MSD is dedicated to identifying and developing metabolic therapies to diminish human pain and sufferings that arise due to inborn errors in metabolism. We seek to utilize groundbreaking clinical and research strategies to fight metabolic disorders like diabetes, obesity, pain and sleep disorders. The outcome of our dedicated research in metabolics available in India are JANUVIA

Vaccines
After dedicating decades towards developing drugs and thereby treating diseases, in 1950s Merck & Co. Inc. saw vaccines as a means of preventing diseases. Many pioneering vaccine discoveries have come from our laboratories. Starting from

developing the first available vaccine for measles in 1963, first vaccines for mumps and rubella in 1960s, we have continued to develop vaccines to fight diseases like pneumonia, Meningitis, Hepatitis A and Hepatitis B. Outcomes of our endeavors to prevent fatal diseases and increase immunity available in India are PNEUMOVAX 23 GARDASIL Cardiovascular COZAAR a (losartan potassium tablets) Prescribing Information Patient Product Information Product Web site

HYZAAR a (losartan potassium-hydrochlorothiazide) Tablets Prescribing Information Patient Product Information Product Web site

INTEGRILIN (eptifibatide) Injection Prescribing Information

MEVACOR (lovastatin) Tablets Prescribing Information

PRINIVIL (lisinopril) Tablets Prescribing Information

PRINZIDE (lisinopril-hydrochlorothiazide) Tablets Prescribing Information

VYTORIN (ezetimibe/simvastatin) Tablets Prescribing Information Patient Product Information Product Web site

ZETIA (ezetimibe) Tablets Prescribing Information Patient Product Information Product Web site

ZOCOR (simvastatin) Tablets Prescribing Information

Vaccines are one of the greatest public health success stories of the 20th
century, and Merck has played its part in that story. We are one of a few companies who remain dedicated to the complex business of researching and producing vaccines. Our unique contributions include the prevention of now rare diseases, like measles and mumps, to diseases never thought preventable, like shingles and cervical cancer. AFLURIA [influenza virus vaccine] Prescribing Information BCG Vaccine Prescribing Information

COMVAX [Haemophilus b conjugate (meningococcal protein conjugate) and hepatitis B (recombinant) vaccine] Prescribing Information GARDASIL [human papillomavirus quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] Prescribing Information Patient Product Information Product Web site

M-M-R II [measles, mumps and rubella virus vaccine live]

Prescribing Information Patient Product Information PEDVAX HIB [Haemophilus b conjugate vaccine (meningococcal protein conjugate)] Prescribing Information

PNEUMOVAX 23 [pneumococcal vaccine polyvalent] Prescribing Information PROQUAD [measles, mumps, rubella and varicella virus vaccine live] Prescribing Information

RECOMBIVAX HB [hepatitis B vaccine (recombinant)] Prescribing Information ROTATEQ Oral Solution [rotavirus vaccine, live, oral, pentavalent] Prescribing Information Patient Product Information Product Web site

TETANUS AND DIPHTHERIA TOXOIDS ADSORBED Prescribing Information

VAQTA [hepatitis A vaccine, inactivated] Prescribing Information

VARIVAX [varicella virus vaccine live] Prescribing Information Patient Product Information ZOSTAVAX [zoster vaccine live] Prescribing Information Patient Product Information Product Web site